117 related articles for article (PubMed ID: 37208019)
1. The KORE-INNOVATION trial, a prospective controlled multi-site clinical study to implement and assess the effects of an innovative peri-operative care pathway for patients with ovarian cancer: rationale, methods and trial design.
Inci MG; Sehouli J; Schnura E; Lee M; Roll S; Reinhold T; Klews J; Kaufner L; Niggemann P; Groeben H; Toelkes J; Reisshauer A; Liebl M; Daehnert E; Zimmermann M; Knappe-Drzikova B; Rolker S; Nunier B; Algharably E; Pirmorady Sehouli A; Zwantleitner L; Krull A; Heitz F; Ataseven B; Chekerov R; Harter P; Schneider S
Int J Gynecol Cancer; 2023 Aug; 33(8):1304-1309. PubMed ID: 37208019
[TBL] [Abstract][Full Text] [Related]
2. TRUST: Trial of Radical Upfront Surgical Therapy in advanced ovarian cancer (ENGOT ov33/AGO-OVAR OP7).
Reuss A; du Bois A; Harter P; Fotopoulou C; Sehouli J; Aletti G; Guyon F; Greggi S; Mosgaard BJ; Reinthaller A; Hilpert F; Schade-Brittinger C; Chi DS; Mahner S
Int J Gynecol Cancer; 2019 Oct; 29(8):1327-1331. PubMed ID: 31420412
[TBL] [Abstract][Full Text] [Related]
3. TRAINING-Ovary 01 (connecTed pRehabiliAtIoN pelvIc caNcer surGery): multicenter randomized study comparing neoadjuvant chemotherapy for patients managed for ovarian cancer with or without a connected pre-habilitation program.
Lambaudie E; Bannier/Braticevic C; Villaron/Goetgheluck C; Zemmour C; Boher JM; Ben Soussan P; Pakradouni J; Brun C; Lopez Almeida L; Marino P
Int J Gynecol Cancer; 2021 Jun; 31(6):920-924. PubMed ID: 33262113
[TBL] [Abstract][Full Text] [Related]
4. PROFAST: A randomised trial implementing enhanced recovery after surgery for highcomplexity advanced ovarian cancer surgery.
Sánchez-Iglesias JL; Carbonell-Socias M; Pérez-Benavente MA; Monreal Clua S; Manrique-Muñoz S; García Gorriz M; Burgos-Peláez R; Segurola Gurrutxaga H; Pamies Serrano M; Pilar Gutiérrez-Barceló MD; Serrano-Castro S; Balcells-Farré MT; Pérez-Barragán C; Scaillet-Houberechts A; Cossio-Gil Y; Gil-Moreno A
Eur J Cancer; 2020 Sep; 136():149-158. PubMed ID: 32688208
[TBL] [Abstract][Full Text] [Related]
5. A multimodal prehabilitation program for the reduction of post-operative complications after surgery in advanced ovarian cancer under an ERAS pathway: a randomized multicenter trial (SOPHIE).
Díaz-Feijoo B; Agusti N; Sebio R; Sisó M; Carreras-Dieguez N; Domingo S; Díaz-Cambronero O; Torne A; Martinez-Palli G; Arguís MJ
Int J Gynecol Cancer; 2022 Jul; ():. PubMed ID: 35793862
[TBL] [Abstract][Full Text] [Related]
6. A prospective study evaluating the impact of implementing the ERAS protocol on patients undergoing surgery for advanced ovarian cancer.
Agarwal R; Rajanbabu A; P V N; Goel G; Madhusudanan L; U G U
Int J Gynecol Cancer; 2019 Mar; 29(3):605-612. PubMed ID: 30833445
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of an enhanced recovery after surgery (ERAS) pathway in a Norwegian cohort of patients with suspected or advanced ovarian cancer.
Lindemann K; Kleppe A; Eyjólfsdóttir B; Heimisdottir Danbolt S; Wang YY; Heli-Haugestøl AG; Walcott SL; Mjåland O; Navestad GA; Hermanrud S; Juul-Hansen KE; Kongsgaard U
Int J Gynecol Cancer; 2023 Aug; 33(8):1279-1286. PubMed ID: 37451690
[TBL] [Abstract][Full Text] [Related]
8. Primary cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC) for FIGO stage III epithelial ovarian cancer: OVHIPEC-2, a phase III randomized clinical trial.
Koole S; van Stein R; Sikorska K; Barton D; Perrin L; Brennan D; Zivanovic O; Mosgaard BJ; Fagotti A; Colombo PE; Sonke G; Driel WJV;
Int J Gynecol Cancer; 2020 Jun; 30(6):888-892. PubMed ID: 32205449
[TBL] [Abstract][Full Text] [Related]
9. Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.
Fagotti A; Ferrandina G; Vizzielli G; Fanfani F; Gallotta V; Chiantera V; Costantini B; Margariti PA; Gueli Alletti S; Cosentino F; Tortorella L; Scambia G
Eur J Cancer; 2016 May; 59():22-33. PubMed ID: 26998845
[TBL] [Abstract][Full Text] [Related]
10. Clinical validation and comparison of the Comprehensive Complication Index and Clavien-Dindo classification in predicting post-operative outcomes after cytoreductive surgery in advanced ovarian cancer.
Kengsakul M; Nieuwenhuyzen-de Boer GM; Udomkarnjananun S; Kerr SJ; van Doorn HC; van Beekhuizen HJ
Int J Gynecol Cancer; 2023 Feb; 33(2):263-270. PubMed ID: 36600504
[TBL] [Abstract][Full Text] [Related]
11. CHRONO: randomized trial of the CHROnology of surgery after Neoadjuvant chemotherapy for Ovarian cancer.
Classe JM; Ferron G; Ouldamer L; Gauthier T; Emambux S; Gladieff L; Dupre PF; Anota A
Int J Gynecol Cancer; 2022 Aug; 32(8):1071-1075. PubMed ID: 35321888
[TBL] [Abstract][Full Text] [Related]
12. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
Jiang R; Zhu J; Kim JW; Liu J; Kato K; Kim HS; Zhang Y; Zhang P; Zhu T; Aoki D; Yu A; Chen X; Wang X; Zhu D; Zhang W; Jia H; Shi T; Gao W; Yin S; Feng Y; Xiang L; Okamoto A; Zang R
J Gynecol Oncol; 2020 Sep; 31(5):e86. PubMed ID: 32808504
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. An exercise and nutrition intervention for ovarian cancer patients during and after first-line chemotherapy (BENITA study): a randomized controlled pilot trial.
Maurer T; von Grundherr J; Patra S; Jaeger A; Becher H; Schmalfeldt B; Zyriax BC; Chang-Claude J
Int J Gynecol Cancer; 2020 Apr; 30(4):541-545. PubMed ID: 31796532
[TBL] [Abstract][Full Text] [Related]
15. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.
Monk BJ; Coleman RL; Fujiwara K; Wilson MK; Oza AM; Oaknin A; O'Malley DM; Lorusso D; Westin SN; Safra T; Herzog TJ; Marmé F; N Eskander R; Lin KK; Shih D; Goble S; Grechko N; Hume S; Maloney L; McNeish IA; Kristeleit RS
Int J Gynecol Cancer; 2021 Dec; 31(12):1589-1594. PubMed ID: 34593565
[TBL] [Abstract][Full Text] [Related]
16. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
[TBL] [Abstract][Full Text] [Related]
17. Laparoscopic management of advanced epithelial ovarian cancer after neoadjuvant chemotherapy: a phase II prospective multicenter non-randomized trial (the CILOVE study).
Pomel C; Akladios C; Lambaudie E; Rouzier R; Ferron G; Lecuru F; Classe JM; Fourchotte V; Paillocher N; Wattiez A; Montoriol PF; Thivat E; Beguinot M; Canis M
Int J Gynecol Cancer; 2021 Dec; 31(12):1572-1578. PubMed ID: 34670829
[TBL] [Abstract][Full Text] [Related]
18. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
[TBL] [Abstract][Full Text] [Related]
19. Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.
Schettino C; Musacchio L; Bartoletti M; Chiodini P; Arenare L; Baldassarre G; Califano D; Capoluongo E; Costi MP; D'Incalci M; Marchini S; Mezzanzanica D; Normanno N; Scala S; Greggi S; Perrone F; Pignata S
Int J Gynecol Cancer; 2022 Jun; 32(6):799-803. PubMed ID: 35318277
[TBL] [Abstract][Full Text] [Related]
20. The impact of Enhanced Recovery after Surgery (ERAS) pathways with regard to perioperative outcome in patients with ovarian cancer.
Reuter S; Woelber L; Trepte CC; Perez D; Zapf A; Cevirme S; Mueller V; Schmalfeldt B; Jaeger A
Arch Gynecol Obstet; 2022 Jul; 306(1):199-207. PubMed ID: 34958401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
